Seattle, Washington — According to state and local economic development sources Sonoma Biotherapeutics plans to invest $375,000.00 to build out new space in Seattle. The company plans to occupy the new space at 410 W Harrison St in Seattle, on or about June 1, 2021. According to the company website Sonoma Biotherapeutics is a privately held, San Francisco and Seattle-based company leading the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

To learn more about Sonoma Biotherapeutics, visit http://www.sonomabio.com/

Company Contact:
Jeffrey Bluestone, Chief Executive Officer
jbluestone@sonomabio.com
https://www.linkedin.com/in/jeffrey-bluestone-4399553/
510-364-7902

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved